Ligand Pharmaceuticals LGND Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's investing cash flow?
- Ligand Pharmaceuticals (LGND) reported investing cash flow of -$94.35M in Q1 2026.
- How has Ligand Pharmaceuticals's investing cash flow changed year-over-year?
- Ligand Pharmaceuticals's investing cash flow decreased by 2027.8% year-over-year, from $4.89M to -$94.35M.
- What is the long-term trend for Ligand Pharmaceuticals's investing cash flow?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's investing cash flow has grown at a 30.2% compound annual growth rate (CAGR), from $170.91M to -$377.32M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.